DAX21.383 -1,6%ESt505.206 -1,5%Top 10 Crypto14,70 -9,8%Dow44.545 -0,8%Nas19.627 -0,3%Bitcoin93.191 -2,1%Euro1,0245 -1,2%Öl76,76 ±-0,0%Gold2.799 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Tesla A1CX3T Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 Palantir A2QA4J BASF BASF11 Microsoft 870747 Deutsche Bank 514000 BVB (Borussia Dortmund) 549309 Bayer BAY001 Amazon 906866 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX tiefer -- Asiens Börsen schließen in Rot: Trump erlässt Strafzölle -- Bitcoin unter Druck -- Zwei Porsche-Vorstände vor dem Aus -- Bayer, Stellantis, Roche, HSBC im Fokus
Top News
Zurückhaltung in Frankfurt: LUS-DAX verbucht am Montagmittag Verluste Zurückhaltung in Frankfurt: LUS-DAX verbucht am Montagmittag Verluste
SIX-Handel Das macht der SPI aktuell SIX-Handel Das macht der SPI aktuell
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Poxel SA Aktie

NeuKaufenVerkaufen
0,2735 EUR +0,0030 EUR +1,11 %
STU
0,2855 EUR -0,0095 EUR -3,22 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.15,33 Mio. EUR

Div. Rendite0,00%

WKNA14M04

ISINFR0012432516

SymbolPXXLF

Poxel SA Aktien News

DatumMeistgelesen
BusinesswirePoxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update
BusinesswirePoxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
BusinesswirePoxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
BusinesswirePoxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
BusinesswirePoxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
BusinesswirePoxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
BusinesswireAvailability of Poxel's 2022 Half-Year Financial Report
BusinesswirePoxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
BusinesswirePoxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
BusinesswirePoxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
BusinesswirePoxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone
BusinesswirePoxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
BusinesswirePoxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
BusinesswirePoxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
BusinesswirePoxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting
BusinesswirePoxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
BusinesswirePoxel Announces its Participation in Upcoming Investor and Scientific Conferences
BusinesswirePoxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
BusinesswirePoxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
BusinesswirePoxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
BusinesswirePoxel Announces Availability of Its 2021 Universal Registration Document
BusinesswirePoxel Announces Its Participation in Upcoming Scientific Conferences
BusinesswirePoxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
finanzen.netPoxel SA legte die Bilanz zum abgelaufenen Quartal vor
BusinesswirePoxel Reports Financial Results for Full Year 2021 and Provides Corporate Update
BusinesswirePoxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
BusinesswirePoxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
BusinesswirePoxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
finanzen.netPoxel SA: Quartalsergebnisse zum jüngsten Jahresviertel
finanzen.netPoxel SA stellte Ergebnisse des abgelaufenen Quartals vor
finanzen.netPoxel SA vermeldete Zahlen zum jüngsten Quartal
Wer­bung

Poxel SA News

Poxel SA News: auf dieser Seite finden Sie alle Poxel SA News und Nachrichten zur Poxel SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Poxel SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Poxel SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.